Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

Regeneron submitted regulatory applications to the FDA for Eylea HD pre-filled syringe and had positive phase 3 clinical trial results in retinal vein occlusion (RVO). Libtayo's year 2024 sales ...

SNY pays REGN a royalty on such sales. Regeneron records global net product sales of Libtayo and pays Sanofi a royalty on such sales. Total Libtayo sales came in at $366.9 million, up 50% year ...

Reports cash, cash equivalents and marketable securities as of December 31 were $36.1M compared with $85.7M as of December 31, 2023. These ...

Libtayo saw global sales jump 50% to $367 million in Q4. These commercial successes translated to a 10% year-over-year revenue. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is expanding these ...

Regeneron Pharmaceuticals ... injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma ...

Regeneron Pharmaceuticals reported fourth-quarter ... collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the Zacks Consensus Estimate ...

The article " Regeneron: Is It the Perfect Biotech Stock for Value and Growth? " first appeared on MarketBeat.